Warren Shlomchik

Summary

Affiliation: Yale University
Country: USA

Publications

  1. ncbi request reprint Antigen presentation in graft-vs-host disease
    Warren D Shlomchik
    Section of Medical Oncology, Yale University School of Medicine, PO Box 208032, 333 Cedar Street, New Haven, CT 06520, USA
    Exp Hematol 31:1187-97. 2003
  2. ncbi request reprint Graft-versus-host disease
    Warren D Shlomchik
    Yale University School of Medicine, sections of Medical Oncology and Immunobiology, PO Box 208032, New Haven, Connecticut 06520, USA
    Nat Rev Immunol 7:340-52. 2007
  3. ncbi request reprint Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
    Loredana Ruggeri
    Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy
    Science 295:2097-100. 2002
  4. pmc Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells
    Britt E Anderson
    Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
    Blood 111:5242-51. 2008
  5. pmc Autocrine/paracrine TGFbeta1 is required for the development of epidermal Langerhans cells
    Daniel H Kaplan
    Department of Dermatology, 2Department of Laboratory Medicine, 3Section of Immunobiology, and 4Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Exp Med 204:2545-52. 2007
  6. ncbi request reprint Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity
    Daniel H Kaplan
    Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Immunity 23:611-20. 2005
  7. ncbi request reprint Donor APCs are required for maximal GVHD but not for GVL
    Catherine C Matte
    Section of Medical Oncology, Yale University School of Medicine, PO Box 208032, 333 Cedar Street, New Haven, Connecticut 06520, USA
    Nat Med 10:987-92. 2004
  8. pmc Langerhans cells are not required for efficient skin graft rejection
    Jagdeep S Obhrai
    Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA
    J Invest Dermatol 128:1950-5. 2008
  9. ncbi request reprint APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease
    Yi Zhang
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Immunol 169:7111-8. 2002
  10. pmc CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL
    Catherine Matte-Martone
    Section of Medical Oncology, Cancer Center, Yale University School of Medicine, New Haven, CT 06520 8032, USA
    Blood 111:3884-92. 2008

Collaborators

Detail Information

Publications18

  1. ncbi request reprint Antigen presentation in graft-vs-host disease
    Warren D Shlomchik
    Section of Medical Oncology, Yale University School of Medicine, PO Box 208032, 333 Cedar Street, New Haven, CT 06520, USA
    Exp Hematol 31:1187-97. 2003
  2. ncbi request reprint Graft-versus-host disease
    Warren D Shlomchik
    Yale University School of Medicine, sections of Medical Oncology and Immunobiology, PO Box 208032, New Haven, Connecticut 06520, USA
    Nat Rev Immunol 7:340-52. 2007
    ..This Review focuses on research in mouse models pursued to achieve this goal...
  3. ncbi request reprint Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
    Loredana Ruggeri
    Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy
    Science 295:2097-100. 2002
    ..NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation...
  4. pmc Effects of donor T-cell trafficking and priming site on graft-versus-host disease induction by naive and memory phenotype CD4 T cells
    Britt E Anderson
    Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA
    Blood 111:5242-51. 2008
    ..Taken together, these data argue against the hypothesis that T(EM) fail to induce GVHD because of inefficient trafficking to LN and PP...
  5. pmc Autocrine/paracrine TGFbeta1 is required for the development of epidermal Langerhans cells
    Daniel H Kaplan
    Department of Dermatology, 2Department of Laboratory Medicine, 3Section of Immunobiology, and 4Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Exp Med 204:2545-52. 2007
    ..Thus, TGFbeta1 derived from LCs acts directly on LCs through an autocrine/paracrine loop, and it is required for LC development and/or survival...
  6. ncbi request reprint Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity
    Daniel H Kaplan
    Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Immunity 23:611-20. 2005
    ..Moreover, we showed that LCs act during the priming and not the effector phase. Thus, LCs not only were dispensable for CHS, but they served to regulate the response, a previously unappreciated function...
  7. ncbi request reprint Donor APCs are required for maximal GVHD but not for GVL
    Catherine C Matte
    Section of Medical Oncology, Yale University School of Medicine, PO Box 208032, 333 Cedar Street, New Haven, Connecticut 06520, USA
    Nat Med 10:987-92. 2004
    ..These studies identify donor APCs as a new target for treating GVHD, which may preserve GVL...
  8. pmc Langerhans cells are not required for efficient skin graft rejection
    Jagdeep S Obhrai
    Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut, USA
    J Invest Dermatol 128:1950-5. 2008
    ..Thus, LCs in the donor graft are required for long-term skin engraftment, which supports a regulatory role for LCs in skin graft acceptance...
  9. ncbi request reprint APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease
    Yi Zhang
    Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Immunol 169:7111-8. 2002
    ..Thus, tissue-resident APCs control the local recruitment of allo-reactive donor T cells and the subsequent development of acute GVHD...
  10. pmc CD8+ but not CD4+ T cells require cognate interactions with target tissues to mediate GVHD across only minor H antigens, whereas both CD4+ and CD8+ T cells require direct leukemic contact to mediate GVL
    Catherine Matte-Martone
    Section of Medical Oncology, Cancer Center, Yale University School of Medicine, New Haven, CT 06520 8032, USA
    Blood 111:3884-92. 2008
    ..Thus, CD4 cells use distinct effector mechanisms in GVHD and GVL: direct cytolytic action is required for GVL but not for GVHD. If these noncytolytic pathways can be inhibited, then GVHD might be ameliorated while preserving GVL...
  11. pmc Effector memory CD4+ T cells mediate graft-versus-leukemia without inducing graft-versus-host disease
    Hong Zheng
    Penn State Milton S Hershey Medical Center, Department of Medicine, Hershey, PA, USA
    Blood 111:2476-84. 2008
    ....
  12. pmc Memory CD4+ T cells do not induce graft-versus-host disease
    Britt E Anderson
    Sections of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    J Clin Invest 112:101-8. 2003
    ..If these murine results are applicable to human alloSCT, selective administration of memory T cells could greatly improve post-transplant immune reconstitution...
  13. ncbi request reprint Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing
    Catherine C Matte
    Yale University School of Medicine, Section of Medical Oncology, PO Box 208032, New Haven, CT 06520, USA
    Blood 103:4353-61. 2004
    ..CD4 GVL did not require target Fas expression. These results suggest that CPCML's GVL sensitivity may in part be explained by the minimal requirements for T-cell killing, and GVL-resistance may be related to MHC II expression...
  14. ncbi request reprint Transplantation's greatest challenges: advances in chronic graft-versus-host disease
    Warren D Shlomchik
    Department of Medical Oncology, Yale University School of Medicine, New Haven, Connecticut, USA
    Biol Blood Marrow Transplant 13:2-10. 2007
    ..In this overview, we address 3 key areas related to chronic GVHD that hold the highest promise for major advances in the near future: pathobiology, response criteria, and therapy...
  15. ncbi request reprint Recipient gammadelta T cells in graft-versus-host disease
    Britt E Anderson
    Blood 107:3808-9; author reply 3809. 2006
  16. ncbi request reprint Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease
    Britt E Anderson
    Department of Laboratory Medicine, Yale University School of Medicine, 333 Cedar St, PO Box 208035, New Haven, CT 06520 8035, USA
    Blood 104:1565-73. 2004
    ..Additional CD4+CD25+ cells also promoted healing of established lesions, suggesting that their effects persist during the evolution of cGVHD...
  17. ncbi request reprint Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ
    Britt E Anderson
    Section of Immunobiology, The Department of Dermatology, Yale University School of Medicine, 333 Cedar St, Box 208035, New Haven, CT 06520 8035, USA
    Blood 105:2227-34. 2005
    ..These results identify differences in APC requirements between CD8-mediated aGVHD and CD4-mediated cGVHD. They further highlight donor APCs as additional targets for GVHD therapy...
  18. ncbi request reprint Target antigens determine graft-versus-host disease phenotype
    Daniel H Kaplan
    Departments of Dermatology, Yale University School of Medicine, New Haven, CT 06520, USA
    J Immunol 173:5467-75. 2004
    ..Thus, the selection of immunodominant Ags determines the target and character of GVHD, providing insight into the genetic basis for different forms of GVHD...

Research Grants14

  1. ALLOIMMUNITY TO CML IN A NOVEL MURINE MODEL
    Warren Shlomchik; Fiscal Year: 2002
    ..D. in immunology and was scientific director of the alloBMT program at the University of Michigan. He has launched a new alloBMT program at Penn and is committed to Dr. Shlomchik's development into an independent clinician scientist. ..
  2. Leukemia Stem Cells: Essential Targets for GVL and Mediators of GVL-Resistance
    Warren D Shlomchik; Fiscal Year: 2010
    ..Unfortunately, for reasons that are unknown, many cancers are resistant to this therapy and this proposal will investigate the biology underlying this differential sensitivity. ..
  3. Dendritic Cell Subsets and Paths of Maturation in Graft-vs.-Host Disease (GVHD)
    Warren Shlomchik; Fiscal Year: 2009
    ..The goals of our studies are to understand how immune cells are activated to cause disease and to modulate this activation so as to improve the safety and efficacy of stem cell transplantation. ..
  4. Dendritic Cell Subsets and Paths of Maturation in Graft-vs.-Host Disease (GVHD)
    Warren Shlomchik; Fiscal Year: 2007
    ..The goals of our studies are to understand how immune cells are activated to cause disease and to modulate this activation so as to improve the safety and efficacy of stem cell transplantation. ..
  5. Graft Versus Leukemia Against Murine Chronic Phase & Blast Crisis CML
    Warren Shlomchik; Fiscal Year: 2007
    ..Using gene deficient recipients, donors, and leukemias, we will examine antigen presentation, T cell polarization, and T cell effector mechanisms in GVL and GVHD. ..
  6. Novel Immunotoxins for Depletion of Dendritic Cells
    Warren Shlomchik; Fiscal Year: 2005
    ..The goal of our work is to prevent this attack, thereby making this therapy safer and more widely applicable ..
  7. Dendritic Cell Subsets and Paths of Maturation in Graft-vs.-Host Disease (GVHD)
    Warren D Shlomchik; Fiscal Year: 2010
    ..The goals of our studies are to understand how immune cells are activated to cause disease and to modulate this activation so as to improve the safety and efficacy of stem cell transplantation. ..